Connect your AI

Avalo Therapeutics AVTX Number of shares of capital stock authorized to issue (in shares)

Other financials

Income statement

Revenue$59.0K-69.3%

Gross profit$963.0K+8,855%

Operating income-$20.9M-42.5%

Net income-$19.6M-49.3%

EPS (diluted)-$0.98+21.6%

Balance sheet

Cash & equivalents$25.3M-79.8%

Total debt$328.0K-59.1%

Total equity$68.3M-44.3%

Total assets$99.9M-27.9%

Cash flow

Operating cash flow-$17.7M-87.1%

CapEx-—

Free cash flow-$15.0M-444%

Valuation

Market cap$946.18M+1,783%

Enterprise value$921.19M-1,342%

P/S1,892.4×+1,852×

Profitability

Gross margin182%+176pp

Operating margin-15,536.1%-17,275pp

Net margin-7,965.8%-10,750pp

FCF margin-11,123.8%-13,374pp

Returns & leverage

Return on equity-88.8%—

Debt / equity0×0.0×

Current ratio7.7×-14.9×

Where this comes from

Reported directly by Avalo Therapeutics in its filing.

Tagged under the XBRL concept avtx:CapitalStockSharesAuthorized.

The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Avalo Therapeutics's number of shares of capital stock authorized to issue (in shares).

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Avalo Therapeutics's number of shares of capital stock authorized to issue (in shares)?: Avalo Therapeutics (AVTX) reported number of shares of capital stock authorized to issue (in shares) of 205M in Q1 2026.
How has Avalo Therapeutics's number of shares of capital stock authorized to issue (in shares) changed year-over-year?: Avalo Therapeutics's number of shares of capital stock authorized to issue (in shares) decreased by 0.0% year-over-year, from 205M to 205M.